|
|
Post by mango on Apr 15, 2020 19:44:32 GMT -5
I recall from the update that it was 10m from the loan, salary reductions, and other expenses. OK let's use $10M....I don't see how Mango gets to that number. Did you not listen to the Call? Michael Castagna said that between the loan, the 20% pay cuts x 10 weeks, and the significant expense reductions ($3M-$5M), it will save the Company roughly around 10M in 2020. The equates to roughly around a full quarter's worth of cash burn that MannKind will save this year by taking those three critical steps. |
|
bkdmd
Researcher
Posts: 79
|
Post by bkdmd on Apr 15, 2020 20:04:42 GMT -5
|
|
|
|
Post by mango on Apr 15, 2020 20:40:53 GMT -5
Now that I have had a chance to listen to the call— • Between the PPP loan, the 20% in pay cuts for 10 weeks, and significant reductions in Company expenses we will save ~$10M this year—which is close to a full quarter's worth of cash burn. • In line for the UT Milestones. The UT Milestones are in MannKind's control. They will hit them. • TreT clinical trial is still on time and will not be significantly impacted by the COVID-19 pandemic. They still hope to file towards the end of this year. • Special close attention is being put towards the Peds Clinical Trial—specifically, the protocol, hiring a Peds Endo, and getting the right clinical investigators. • The Peds Clinical Trial is of utmost importance to the Company, and is not taking a back seat per-say, but being carefully crafted and fine-tuned so it blooms into an epically beautiful scientific achievement. • Interviewing for a Chief Commercial Officer • 4 potential COVID-19 drugs are being worked on. Is not costing the Company anything per-say, other than maybe a thousand dollars here and there. —The audio was not entirely clear, and I played it back several times, but I believe I hear Michael Castagna saying Curcumin. itellthefuture777 showed us a PR that included this as well, so I believe this confirms that is at least one of the therapies MannKind is working on. Someone needs to verify what he said, but I am 95% sure he says Curcumin—and mentions two versions for this, a potential OTC and prescription version. (Apologies if Curcumin is not what he said, the audio is fuzzy and not clear, but this is what I hear) —One of the therapies doesn't sound very promising, and the third and fourth sound highly plausible and Michael said they are also exciting. • New Corporate Website launch tomorrow Overall, good call. I appreciate Mike doing the more frequent updates and I gained a lot more insight from this call. Overall, I feel good about things, especially the cash situation. |
|
|
|
Post by itellthefuture777 on Apr 15, 2020 21:49:16 GMT -5
|
|
|
|
Post by gamblerjag on Apr 15, 2020 23:03:25 GMT -5
Now that I have had a chance to listen to the call— • Between the PPP loan, the 20% in pay cuts for 10 weeks, and significant reductions in Company expenses we will save ~$10M this year—which is close to a full quarter's worth of cash burn. • In line for the UT Milestones. The UT Milestones are in MannKind's control. They will hit them. • TreT clinical trial is still on time and will not be significantly impacted by the COVID-19 pandemic. They still hope to file towards the end of this year. • Special close attention is being put towards the Peds Clinical Trial—specifically, the protocol, hiring a Peds Endo, and getting the right clinical investigators. • The Peds Clinical Trial is of utmost importance to the Company, and is not taking a back seat per-say, but being carefully crafted and fine-tuned so it blooms into an epically beautiful scientific achievement. • Interviewing for a Chief Commercial Officer • 4 potential COVID-19 drugs are being worked on. Is not costing the Company anything per-say, other than maybe a thousand dollars here and there. —The audio was not entirely clear, and I played it back several times, but I believe I hear Michael Castagna saying Curcumin. itellthefuture777 showed us a PR that included this as well, so I believe this confirms that is at least one of the therapies MannKind is working on. Someone needs to verify what he said, but I am 95% sure he says Curcumin—and mentions two versions for this, a potential OTC and prescription version. (Apologies if Curcumin is not what he said, the audio is fuzzy and not clear, but this is what I hear) —One of the therapies doesn't sound very promising, and the third and fourth sound highly plausible and Michael said they are also exciting. • New Corporate Website launch tomorrow Overall, good call. I appreciate Mike doing the more frequent updates and I gained a lot more insight from this call. Overall, I feel good about things, especially the cash situation. And net 1 million after the commercials :-) |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2020 23:46:22 GMT -5
OK let's use $10M....I don't see how Mango gets to that number. Did you not listen to the Call? Michael Castagna said that between the loan, the 20% pay cuts x 10 weeks, and the significant expense reductions ($3M-$5M), it will save the Company roughly around 10M in 2020. The equates to roughly around a full quarter's worth of cash burn that MannKind will save this year by taking those three critical steps. You are correct. I did a replay of the call. |
|
|
|
Post by boca1girl on Apr 16, 2020 8:07:55 GMT -5
Did anyone hear any mention of the “undisclosed” UT molecule that they gave MNKD $10M for?
|
|
|
|
Post by goyocafe on Apr 16, 2020 8:28:21 GMT -5
|
|
|
|
Post by boca1girl on Apr 16, 2020 8:37:06 GMT -5
Thanks, but there was no mention, no timeline given? |
|
|
|
Post by mango on Apr 16, 2020 9:12:38 GMT -5
Thanks, but there was no mention, no timeline given? Nope. It looks like UT can trigger it whenever they want. My guess is they are waiting to see how TreT performs in the clinical trial and/or FDA approval before moving forward with another molecule with MannKind. That makes sense if it's what they are actually thinking. MannKind has rights to Tadalafil for indications outside PAH scope. Doubt they will go after ED now that the focus has changed to rare lung diseases, unless they are wanting to out-license it. |
|
|
|
Post by jlaw277 on Apr 16, 2020 9:32:43 GMT -5
Now that I have had a chance to listen to the call— • Between the PPP loan, the 20% in pay cuts for 10 weeks, and significant reductions in Company expenses we will save ~$10M this year—which is close to a full quarter's worth of cash burn. • In line for the UT Milestones. The UT Milestones are in MannKind's control. They will hit them. • TreT clinical trial is still on time and will not be significantly impacted by the COVID-19 pandemic. They still hope to file towards the end of this year. • Special close attention is being put towards the Peds Clinical Trial—specifically, the protocol, hiring a Peds Endo, and getting the right clinical investigators. • The Peds Clinical Trial is of utmost importance to the Company, and is not taking a back seat per-say, but being carefully crafted and fine-tuned so it blooms into an epically beautiful scientific achievement. • Interviewing for a Chief Commercial Officer • 4 potential COVID-19 drugs are being worked on. Is not costing the Company anything per-say, other than maybe a thousand dollars here and there. —The audio was not entirely clear, and I played it back several times, but I believe I hear Michael Castagna saying Curcumin. itellthefuture777 showed us a PR that included this as well, so I believe this confirms that is at least one of the therapies MannKind is working on. Someone needs to verify what he said, but I am 95% sure he says Curcumin—and mentions two versions for this, a potential OTC and prescription version. (Apologies if Curcumin is not what he said, the audio is fuzzy and not clear, but this is what I hear) —One of the therapies doesn't sound very promising, and the third and fourth sound highly plausible and Michael said they are also exciting. • New Corporate Website launch tomorrow Overall, good call. I appreciate Mike doing the more frequent updates and I gained a lot more insight from this call. Overall, I feel good about things, especially the cash situation. From an Immix press release: About Imx-110Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. Imx-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models — with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone, and a wholesale shift in the tumor microenvironment post administration. Press release link |
|
